Analytical Report on Biocept inc (NASDAQ:BIOC)


Biocept inc (NASDAQ:BIOC) currently has a “Hold” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Biocept inc (NASDAQ:BIOC) lost -17.3 Percent and closed its previous trading session at $6.55. The stock traded with the average Volume of 128.66 Million at the end of last session.

Biocept inc (NASDAQ:BIOC) has the Market Capitalization of 516.73 Million. The Stock has its 52-week High of $49.20 and 52-Week Low of $ 3.50 and it touched its 52-week high on 07/14/17 and 52-Week Low on 07/11/18


The company reported its last earnings Actual EPS of $-0.11/share. While, the analyst predicted that the company could provide an EPS of $-0.09/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.02/share which shows an Earnings Surprise of -22.2 Percent.

Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Biocept inc (NASDAQ:BIOC) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 1.62% where SMA50 and SMA200 are 3.65% and -57.41% respectively.

The company shows its Return on Assets (ROA) value of -196.6%. The Return on Equity (ROE) value stands at -444.7%. While it’s Return on Investment (ROI) value is -452.7%.

Biocept inc (NASDAQ:BIOC) currently has a Weekly Volatility of 47.95% percent while its Monthly Volatility is at 23.30% percent. While talking about Performance of the Stock, Biocept inc currently has a Weekly performance of 24.76%, monthly performance percentage is -1.65 percent, Quarterly performance is -14.28 percent, 6 months performance shows a percent value of -69.67% and Yearly Performance is -84.62 percent.

Company Profile:

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California.